+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Vasotocin Biosynthesis by Neurohypophysial Cells from Human Fetuses. Evidence for its Ependymal Origin

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Cultured neurohypophysial cells from human fetuses aged 130–155 days release into the culture medium an active principle which has antidiuretic, hydroosmotic and rat uterine activities. The chromatographic mobility of the active principle, as well as the susceptibility of all of the above activities to tryptic digestion, indicates the presence of a basic peptide identical to arginine vasotocin (AVT). The ability of these cultured cells, which are probably ependymal cells, to release the above activities during 43 days of incubation, suggests that AVT is synthesized and secreted by specialized ependymal cells in the developing human neurohypophysis. Neither in the culture media from anterior pituitaries of the same fetuses nor in control culture media could antidiuretic, rat uterine or hydroosmotic activities be detected. Although the nonincubated neurohypophyses of the same age contain pharmacological activities suggesting the presence of vasopressin, oxytocin and AVT, the neurohypophysial cells cultured in vitro apparently release only AVT into the medium. This supports the suggestion that whereas vasopressin and oxytocin are synthesized in the hypothalamic neurosecretory cells, AVT, on the contrary, appears to be synthesized by ependymal neurohypophysial cells in the developing human neurohypophysis. Consequently, the fetal human neurohypophysis, and presumably the fetal mammalian neurohypophysis, appears not only as a storage site for neurohypophysial hormones but also as an endocrine structure which synthesizes and secretes AVT by ependymosecretion.

          Related collections

          Author and article information

          S. Karger AG
          20 March 2008
          : 19
          : 2
          : 150-159
          Institute of Endocrinology, Bucharest
          122435 Neuroendocrinology 1975;19:150–159
          © 1975 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10


          Comment on this article